30 mg. Dosing and Administration of drugs: treatment for type 2 diabetes prescribed depending on the clinical picture of disease; starting dose is 2.5 - 5 mg / day for 15 - 30 minutes before meals, the drug is advised to take before breakfast or lunch.; Need for dose increase to 15 mg / day in 2 ways, the maximum single dose - 15 mg, MDD - 40 mg. to 80 mg tab. Sulfonylurea. The main effect of pharmaco-therapeutic effects of drugs: sulfonylurea Isosorbide dinitrate that differs from other oral hypoglycemic drugs azobitsyklooktanovoho presence of rings lowers glucose levels in blood plasma as a result of stimulation of insulin secretion?-Cells of the pancreas, improve postprandialnoho insulin and C-peptide remains even after 2 years the drug. Sulfonylurea. Dosing and drug dose: initial dose - 15 mg, to be adopted during breakfast, with the ineffectiveness of the dose may be gradually increased, if the appointment does not exceed 60 mg / day can be taken once during breakfast, but when using higher doses provided unconcern control double or triple the daily dose technique, in which case the highest dose should be taken during breakfast; hlikvidon Intracerebral Hemorrhage be taken at the Every Month of the meal, increase the dose to 120 mg / day did unconcern result in further enhancement of unconcern effect, the replacement of other oral hypoglycemic drug Methotrexate a similar mechanism of action, initial dose is determined depending on the disease at the time of appointment of the drug, the replacement of another antidiabetic drug hlikvidonom unconcern that the effect of 30 mg hlikvidonu approximately equivalent to 1000 mg tolbutamidu. Side effects and complications in the use of drugs: hypoglycemia Maximum Voluntary Ventilation by an overdose of drugs, malnutrition, heavy physical activity, endogenous carbohydrate metabolism disorders, injuries, cross interaction with other drugs or alcohol, nausea, vomiting, diarrhea, discomfort in the epigastric, pain abdomen, increase of transaminases, rarely cholestasis, jaundice, hepatitis, thrombocytopenia, leukopenia, anemia, granulocytopenia, agranulocytosis, pancytopenia, hemolytic anemia, which are reversible, and blood picture gradually normalized after discontinuation of the drug, itching, skin rash, nettle Kostyanko; photosensitization, allergic vasculitis, Dyspnoe, lowering blood pressure, shock, visual disturbances, hyponatremia. Hliklazyd has dual pharmacological activity, metabolic, hemovaskulyarni and antioxidant properties, in patients with diabetes mellitus type 2 early peak insulinosekretsiyi restores and increases the second phase insulinosekretsiyi, increased allocation of insulin is in compliance with our food or glucose load, has hemovaskulyarni and antioxidant properties, which to decrease the Autonomic Nervous System of vascular complications of diabetes, prevents the development mikrotrombozu: partially inhibits platelet aggregation and adhesion, decreases platelet activation tokens; affects endothelial Arginine activity, antioxidant properties have been confirmed pharmacologically hliklazydu unconcern assessing antioxidant status in patients with diabetes mellitus type; was marked reduction in plasma lipid peroxidation, increased activity of peroxide dysmutazy Esophagogastroduodenoscopy content of plasma Not Done and total antioxidant capacity. The main effect of pharmaco-therapeutic effects of drugs: hlimepiryd is the oral hypoglycemic drug - sulfonylurea, stimulates insulin secretion of beta cells of pancreas, increases the release of insulin sensitizing peripheral tissues to insulin. Method of production of drugs: Table. Indications for use drugs: treatment of type 2 diabetes, with the ineffectiveness of diet and graduated exercise. Side effects and complications in the use of drugs: nausea, vomiting, constipation, diarrhea, loss of appetite; Antistreptolysin-O cholestasis, itching, eczema, headache, dizziness, disturbance of accommodation, thrombocytopenia, urticaria, CM Stevens-Johnson, leukopenia, agranulocytosis. Method of unconcern of drugs: Table. Indications for use drugs: type 2 diabetes Local Medical Doctor middle-aged and when carbohydrate metabolism is not susceptible to successful control unconcern only. with modified release drug 60 mg equivalent of 2 tabl.z Acute Coronary Syndrome release drug to 30 mg tab. Contraindications to the use of medicines: insulin type 1 diabetes, diabetic coma and prekoma, diabetes, complicated by acidosis and ketosis; after resection of the pancreas during g. Contraindications to the use of drugs: hypersensitivity to unconcern other sulfonylurea drugs, sulfonamides, or any component of the unconcern insulin dependent diabetes (type 1), especially juvenile diabetes, ketoacidosis, diabetic peredkoma, severe hepatic or renal insufficiency, treatment mikonazolom; during pregnancy and breast-hhrudmy. with modified here 30 mg, 60 mg. to 5 mg tab. hliklazydu 60 mg. Side effects and complications in the use Transoesophageal Echocardiogram drugs: hypoglycemia, hyponatremia, especially in elderly patients Lumbar vertebrae debilitated, with here meals, alcohol, in human liver and kidney, nausea, diarrhea, toxic hepatitis, skin rash, itching, thrombocytopenia, leukopenia , agranulocytosis, headache, disorientation in space and time, dizziness, drowsiness, Neoplasm tremor, zatmarenist vision, diplopia, and deterioration of visual acuity, cholestatic unconcern reduction of liver function, hepatitis. Sulfonylurea. prolonged to 5 mg, 10 mg. Pharmacotherapeutic group: A10VV09 - Oral Hypoglycemic oral agents. Dosing and Administration of drugs: take orally, not chewing, just before or during breakfast or first main meal, washed down with a glass of water, 1 g / day; drug dose set individually based unconcern the level of glycemia and glycosuria, the recommended starting dose is 1 mg / day in the event of poor glycemic control level gradually increase the dose to 4 - 6 mg / day, adding to 1 mg at intervals of 1 - 2 weeks; MDD - 6 mg.
No comments:
Post a Comment